News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fedora Pharmaceuticals Inc. Appoints Thomas R. Parr, Ph.D., Chief Scientific Officer



9/5/2012 9:18:35 AM

EDMONTON, Alberta, Sept. 5, 2012 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced the appointment of Thomas Parr, Ph.D. to the newly created role of chief scientific officer. Dr. Parr was most recently chief scientific officer at Targanta Therapeutics, where he was instrumental in the development of oritavancin, a lipoglycopeptide for the treatment of Gram-positive bacterial infections.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES